<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1210222719
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEFAFOUR 2 gm IV/IM Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFEPIME HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        57.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DE01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cefafour is indicated in the treatment of infections caused by bacteria susceptible to cefepime, namely:</p><ul><li>Lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis</li><li>Uncomplicated and complicated urinary tract infections, including pyelonephritis</li><li>Skin and subcutaneous tissue infection</li><li>Intrabdominal infection, including peritonitis, and biliary tract infections</li><li>Gynecological infections</li><li>Bacterial meningitis in infants and children</li><li>In combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection</li><li>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</li></ul><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Cefafour</strong></p><ul><li>If you are allergic to cefepime, any other cephalosporin antibiotics or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have history of severe allergic reaction to any other type of beta-lactam antibiotics (penicillins, monobactams and carbapenems).</li></ul><p><strong>Warnings and Precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Cefafour.</p><p><em>Particular care should be taken when using cefepime</em><em>:</em></p><ul><li>Severe and occasionally fatal allergic reactions were reported. Please tell your doctor if you have a history of asthma or allergic reactions (skin rash, itching&hellip;). Severe allergic reactions may need epinephrine and other support therapy.</li><li>Cefepime is not adequate for the treatment of certain types of infections. Your doctor has prescribed you this antibiotic because it is the best option for your illness.</li><li>If you have kidney problems (such as reduced renal function) as the elimination of this medicine may be affected.</li><li>If you suffer from persistent diarrhoea during or after using this medicine. Tell your doctor immediately so he can investigate whether the diarrhoea is the result of an intestinal inflammation caused by the use of the antibiotic; treatment with this medicine may need to be discontinued.</li><li>If you suffer from allergies (such as hay fever, nettle rash) or have had an allergic reaction to medicines in the past. Cefepime must be discontinued on the appearance of any kind of hypersensitivity reaction and appropriate therapeutic measures initiated.</li><li>Dosages for elderly patients should be chosen carefully and should take renal function into account, as there is a greater possibility to develop kidney disease.</li></ul><p><strong>Other medicines and Cefafour</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines, including medicines obtained without prescription.</p><p>Renal function should be carefully monitored when Cefafour is combined with drugs that may affect the kidneys (such as aminoglycosides and powerful diuretics).</p><p>The cephalosporins may enhance the effect of coumarin anticoagulants.</p><p><em>Interaction with diagnostic tests</em></p><p>Cefepime may produce a false positive reaction in some laboratory tests (urine glucose and Coombs test results).</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>Do not use this medicine during pregnancy, unless absolutely necessary and specifically directed by your doctor. If you get pregnant during treatment with cefepime tell your doctor.</p><p>Cefepime can be transferred to breast milk, therefore this medicine should be used during breast-feeding with great care and only after discussing with your doctor.</p><p><strong>Driving and using machines </strong></p><p>There have been no studies on the effects on the ability to drive and use machines.</p><p>However, you may experience disturbed consciousness, dizziness, confusion and hallucination, which may compromise the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Cefafour can be administered via intravenous use or intramuscular use.</p><p>After reconstitution the solution is yellow to yellow-brown.</p><p>The usual dose and the route of administration vary in accordance with the severity of the infection, the renal function and the general conditions of the patient.</p><p>The IV route of administration is preferable in the patients with severe infections or in a life-threatening situation, particularly if there is the possibility of shock.</p><p>For adult patients and children with a body weight &gt; 40 kg, with normal renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top; width:353px"><p><strong>Seve</strong><strong>ri</strong><strong>t</strong><strong>y of the infection</strong></p></td><td style="vertical-align:top; width:341px"><p><strong>Dosa</strong><strong>g</strong><strong>e and route of administration</strong></p></td><td style="vertical-align:top; width:641px"><p><strong>Interval between doses </strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:353px"><p>Mild to moderate urinary tract infections (UTI)</p></td><td style="vertical-align:top; width:341px"><p>500 mg to 1000 mg IV or IM</p></td><td style="vertical-align:top; width:641px"><p>every 12 h</p></td></tr><tr><td style="vertical-align:top; width:353px"><p>Other mild to moderate infections (non UTI)</p></td><td style="vertical-align:top; width:341px"><p>1000 mg IV or IM</p></td><td style="vertical-align:top; width:641px"><p>every 12 h</p></td></tr><tr><td style="vertical-align:top; width:353px"><p>Severe infection</p></td><td style="vertical-align:top; width:341px"><p>2000 mg IV</p></td><td style="vertical-align:top; width:641px"><p>every 12 h</p></td></tr><tr><td style="vertical-align:top; width:353px"><p>Very severe infection or life-threatening infections</p></td><td style="vertical-align:top; width:341px"><p>2000 mg IV</p></td><td style="vertical-align:top; width:641px"><p>every 8 h</p></td></tr></tbody></table><p>The usual duration of treatment is 7 to 10 days; more serious infections may require a longer treatment. In the empiric treatment of febrile neutropenia, the usual treatment duration should not be less than 7 days or until the resolution of the neutropenia.</p><p>In patients with a body weight &le; 40 kg, the recommended dosage for children applies.</p><p><strong>Use in children </strong></p><p><em>For children with normal renal function: </em></p><p>In children the recommended dose is:</p><ul><li>Pneumonia, urinary tract infections, skin and subcutaneous tissue infection:<ul><li>Children aged more than 2 months and weighing &le; 40 kg: 50 mg/kg every 12 hours for 10 days; in more severe infections, the 8 hours interval between the intakes should be done.</li></ul></li><li>Bacteraemia that occurs in association with, or is suspected to be associated infections, bacterial meningitis and empirical treatment of febrile neutropenia:<ul><li>Children aged more than 2 months and weighing &le; 40 kg: 50 mg/kg every 8 hours during 7 to 10 days.</li></ul></li></ul><p>Experience in children under 2 months of age is limited. Children of this age should be monitored carefully during administration of cefepime.</p><p>In children with body weight &gt; 40 kg, the adult dosage is recommended.</p><p>Do not exceed the maximum recommended adult dose (2000 mg every 8 hours). Experience with the intramuscular route in children is limited.</p><p><em>Elderly, patients with renal dysfunction, dialysis patients and children with renal dysfunction:</em></p><p>The doctor will determine the dose to be administered.</p><p><strong>If you use more </strong><strong>Cefafour </strong><strong>than you should</strong></p><p>Contact your doctor or other healthcare professionals immediately, as you may experience more severe side effects under certain situations.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Cefafour can be administered via intravenous use or intramuscular use.</p><p>After reconstitution the solution is yellow to yellow-brown.</p><p>The usual dose and the route of administration vary in accordance with the severity of the infection, the renal function and the general conditions of the patient.</p><p>The IV route of administration is preferable in the patients with severe infections or in a life-threatening situation, particularly if there is the possibility of shock.</p><p>For adult patients and children with a body weight &gt; 40 kg, with normal renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top; width:402px"><p><strong>Seve</strong><strong>ri</strong><strong>t</strong><strong>y of the infection</strong></p></td><td style="vertical-align:top; width:408px"><p><strong>Dosa</strong><strong>g</strong><strong>e and route of administration</strong></p></td><td style="vertical-align:top; width:526px"><p><strong>Interval between doses </strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:402px"><p>Mild to moderate urinary tract infections (UTI)</p></td><td style="vertical-align:top; width:408px"><p>500 mg to 1000 mg IV or IM</p></td><td style="vertical-align:top; width:526px"><p>every 12 h</p></td></tr><tr><td style="vertical-align:top; width:402px"><p>Other mild to moderate infections (non UTI)</p></td><td style="vertical-align:top; width:408px"><p>1000 mg IV or IM</p></td><td style="vertical-align:top; width:526px"><p>every 12 h<strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:402px"><p>Severe infection</p></td><td style="vertical-align:top; width:408px"><p>2000 mg IV</p></td><td style="vertical-align:top; width:526px"><p>every 12 h</p></td></tr><tr><td style="vertical-align:top; width:402px"><p>Very severe infection or life-threatening infections</p></td><td style="vertical-align:top; width:408px"><p>2000 mg IV</p></td><td style="vertical-align:top; width:526px"><p>every 8 h</p></td></tr></tbody></table><p>The usual duration of treatment is 7 to 10 days; more serious infections may require a longer treatment. In the empiric treatment of febrile neutropenia, the usual treatment duration should not be less than 7 days or until the resolution of the neutropenia.</p><p>In patients with a body weight &le; 40 kg, the recommended dosage for children applies.</p><p><strong>Use in children </strong></p><p><em>For children with normal renal function: </em></p><p>In children the recommended dose is:</p><ul><li>Pneumonia, urinary tract infections, skin and subcutaneous tissue infection:<ul><li>Children aged more than 2 months and weighing &le; 40 kg: 50 mg/kg every 12 hours for 10 days; in more severe infections, the 8 hours interval between the intakes should be done.</li></ul></li><li>Bacteraemia that occurs in association with, or is suspected to be associated infections, bacterial meningitis and empirical treatment of febrile neutropenia:<ul><li>Children aged more than 2 months and weighing &le; 40 kg: 50 mg/kg every 8 hours during 7 to 10 days.</li></ul></li></ul><p>Experience in children under 2 months of age is limited. Children of this age should be monitored carefully during administration of cefepime.</p><p>In children with body weight &gt; 40 kg, the adult dosage is recommended.</p><p>Do not exceed the maximum recommended adult dose (2000 mg every 8 hours). Experience with the intramuscular route in children is limited.</p><p><em>Elderly, patients with renal dysfunction, dialysis patients and children with renal dysfunction:</em></p><p>The doctor will determine the dose to be administered.</p><p><strong>If you use more </strong><strong>Cefafour </strong><strong>than you should</strong></p><p>Contact your doctor or other healthcare professionals immediately, as you may experience more severe side effects under certain situations.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p><strong>After reconstitution/dilution</strong></p><p>The in use physical and chemical stability was demonstrated for 24 hours at room temperature and for 7 days in a refrigerator (2-8&deg;C).</p><p>From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use time and storage conditions prior to administration are users&#39; responsibility and, usually, should not exceed 24 hours at 2-8&deg;C, unless reconstitution has occurred under validated aseptic controlled conditions.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cefepime hydrochloride monohydrate.</p><p>Each vial of Cefafour 1000 mg Powder for Solution for Injection/Infusion contains cefepime hydrochloride monohydrate equivalent to 1000 mg cefepime.</p><p>Each vial of Cefafour 2000 mg Powder for Solution for Injection/Infusion contains cefepime hydrochloride monohydrate equivalent to 2000 mg cefepime.</p><p>The other ingredient is L-arginine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cefafour 1000 mg Powder for Solution for Injection/Infusion is a white to off-white powder, uniform and free from visible particles in 10 ml type III vials with grey rubber stoppers and flip-off caps. 

Cefafour 2000 mg Powder for Solution for Injection/Infusion is a white to off-white powder, uniform and free from visible particles in 50 ml type II vials with grey rubber stoppers and flip-off caps.

After reconstitution the solution is yellow to yellow-brown.

Pack size: 1 Vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2023; version number SA2.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يوصى باستخدام سيفافور في علاج حالات العدوى التي تسببها البكتيريا الحساسة لسيفيبيم، وهي:</p><ul dir="rtl"><li>حالات عدوى الجهاز التنفسي السفلي، بما في ذلك الالتهاب الرئوي المكتسب من المستشفيات والالتهاب الرئوي المكتسب من المجتمع، والتفاقم البكتيري الحاد لالتهاب الشعب الهوائية المزمن، والعدوى البكتيرية الثانوية لالتهاب الشعب الهوائية الحاد</li><li>التهابات المسالك البولية المصحوبة وغير المصحوبة بمضاعفات، بما في ذلك التهاب الحويضة والكلية</li><li>عدوى الجلد والأنسجة تحت الجلد</li><li>عدوى داخل البطن، بما في ذلك التهاب الصفاق، والتهابات القناة الصفراوية</li><li>حالات عدوى أمراض النساء</li><li>التهاب السحايا البكتيري عند الرضع والأطفال</li><li>بالاشتراك مع عوامل أخرى مضادة للبكتيريا في علاج مرضى قلة العدلات المصابين بحمى يُشتبه في أن تكون بسبب عدوى بكتيرية</li><li>علاج المرضى الذين يعانون من تجرثم الدم المرتبط أو المشتبه ارتباطه بأي من حالات العدوى المذكورة أعلاه.</li></ul><p dir="RTL">ينبغي الاهتمام بالتوجيه الرسمي بشأن الاستخدام المناسب للعوامل المضادة للبكتيريا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم سيفافور</strong></p><ul dir="rtl"><li>إذا كنت تُعاني من تحسس لسيفيبيم، أو أي من مضادات السيفالوسبورين الحيوية الأخرى أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</li><li>إذا كان لديك تاريخ مرضي من رد الفعل التحسسي الشديد لأي نوع آخر من مضادات بيتا لاكتام الحيوية (البنسلين، والمونوباكتامات، والكاربابينيمات).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل استخدام سيفافور.</p><p dir="RTL"><em>يجب</em><em> </em><em>تحديداً</em><em> توخي الحذر عند استخدام سيفيبيم:</em></p><ul dir="rtl"><li>تم الإبلاغ عن ردود فعل تحسسية حادة ومميتة في بعض الأحيان. يُرجى إخبار طبيبك إذا كان لديك تاريخ مرضي بالربو أو ردود فعل تحسسية (طفح جلدي، حكة ...). قد تحتاج ردود الفعل التحسسية الشديدة إلى إبينفرين وعلاجات داعمة أخرى.</li><li>سيفيبيم ليس كافياً لعلاج أنواع معينة من حالات العدوى. لقد وصف لك طبيبك هذا المضاد الحيوي لأنه الخيار الأفضل لعلاج مرضك.</li><li>إذا كنت تُعاني من مشاكل في الكلى (مثل انخفاض وظائف الكلى)، فقد تتأثر إمكانية التخلص من هذا الدواء.</li><li>إذا كنت تُعاني من إسهال مستمر أثناء استخدام هذا الدواء أو بعده. أخبر طبيبك على الفور حتى يتمكن من التحقق مما إذا كان الإسهال ناتجاً عن التهاب معوي بسبب استخدام المضاد الحيوي؛ وحينها قد يلزم التوقف عن العلاج بهذا الدواء.</li><li>إذا كنت تعاني من حساسيات (مثل حمى القش، الطفح الجلدي) أو سبق أن أصبت برد فعل تحسسي تجاه الأدوية في الماضي. يجب إيقاف سيفيبيم عند ظهور أي نوع من تفاعلات فرط الحساسية واتخاذ التدابير العلاجية المناسبة.</li><li>يجب اختيار جرعات المرضى من كبار السن بعناية، ويجب أخذ وظائف الكلى في الاعتبار، حيث تزداد احتمالية الإصابة بمرض كُلوي.</li></ul><p dir="RTL"><strong>الأدوية الأخرى وسيفافور</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستخدم، استخدمت مؤخراً أو قد تستخدم أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">تجب مُراقبة وظائف الكلى بعناية عند إعطاء سيفافور مع أدوية قد تؤثر على الكلى (مثل الأمينوغليكوزيدات ومدرات البول القوية).</p><p dir="RTL">قد تُعزز السيفالوسبورينات تأثير مضادات التخثر من نوع كومارين.</p><p dir="RTL"><em>التفاعل مع الاختبارات التشخيصية</em></p><p dir="RTL">قد ينتج عن سيفيبيم تفاعل إيجابي كاذب في بعض الاختبارات المعملية (نتائج اختبار الجلوكوز في البول ونتائج اختبار كومبس).</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">يرجى استشارة طبيبك أو الصيدلي قبل استخدام هذا الدواء إذا كنتِ حاملاً أو مرضعاً، تعتقدين بأنك حامل أو تخططين لذلك.</p><p dir="RTL">&nbsp;لا تستخدمي هذا الدواء في أثناء الحمل، إلا إذا كان ذلك ضرورياً للغاية ووفقاً لتوجيهات طبيبك على وجه التحديد. إذا أصبحتِ حاملاً في أثناء العلاج بسيفيبيم، أخبري طبيبك بذلك.</p><p dir="RTL">يمكن انتقال سيفيبيم إلى حليب الأم، لذلك يجب توخي الحذر الشديد عند استخدام هذا الدواء في أثناء الرضاعة الطبيعية وبعد مناقشة الأمر مع طبيبكِ فحسب.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">&nbsp;لم يتم إجراء أي دراسات عن التأثيرات على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">ومع ذلك، قد تُصاب باضطراب في الوعي، دوخة، ارتباك وهلوسة، ما قد يضر بالقدرة على القيادة واستخدام الآلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً باستخدام دوائك كما وصفه لك طبيبك أو الصيدلي تماماً. تأكد من طبيبك أو الصيدلي إذا كانت لديك أية استفسارات أو إذا لم تكن متأكداً.</p><p dir="RTL">يمكن إعطاء سيفافور بالحقن الوريدي أو العضلي.</p><p dir="RTL">بعد الحلّ، يكون لون المحلول ما بين الأصفر والأصفر البني.</p><p dir="RTL">تختلف الجرعة المعتادة وطريقة الإعطاء وفقاً لشدة العدوى، وظيفة الكلى والظروف العامة للمريض.</p><p dir="RTL">يفضل إعطاء الحقن الوريدي عند المرضى الذين يعانون من عدوى حادة أو حالة مهددة للحياة، خاصة إذا كان هناك فرصة لحدوث صدمة.</p><p dir="RTL">بالنسبة للمرضى البالغين والأطفال الذين تزيد أوزانهم عن 40 كغم، والذين تكون وظائف الكلى طبيعية لديهم:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>شدة الإصابة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة وطريقة الإعطاء</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الفاصل الزمني بين الجرعات </strong></p><p dir="LTR"><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهابات المسالك البولية الخفيفة إلى المتوسطة (التهاب المسالك البولية)</p></td><td style="vertical-align:top"><p dir="RTL">500 ملغم إلى 1000 ملغم<strong> </strong>عن طريق الحقن الوريدي أو العضلي</p></td><td style="vertical-align:top"><p dir="RTL">كل 12 ساعة<strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهابات أخرى خفيفة إلى متوسطة (غير التهاب المسالك البولية)</p></td><td style="vertical-align:top"><p dir="RTL">1000 ملغم عن طريق الحقن الوريدي أو العضلي</p></td><td style="vertical-align:top"><p dir="RTL">كل 12 ساعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حالات العدوى الشديدة</p></td><td style="vertical-align:top"><p dir="RTL">2000 ملغم عن طريق الحقن الوريدي</p></td><td style="vertical-align:top"><p dir="RTL">كل 12 ساعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حالات العدوى الشديدة جداً أو المهددة للحياة</p></td><td style="vertical-align:top"><p dir="RTL">2000 ملغم عن طريق الحقن الوريدي</p></td><td style="vertical-align:top"><p dir="RTL">كل 8 ساعات</p></td></tr></tbody></table><p dir="RTL">تبلغ الفترة المعتادة للعلاج من 7 إلى 10 أيام؛ وقد تتطلب حالات العدوى الأخطر فترة علاج أطول. في العلاج التجريبي لقلة العدلات الحموية، يجب ألا تقل فترة العلاج المعتادة عن 7 أيام أو حتى علاج قلة العدلات.</p><p dir="RTL">للمرضى الذي تبلغ أوزانهم 40 كغم أو أقل، يتم استخدام الجرعة الموصى بها للأطفال.</p><p dir="RTL"><strong>الاستخدام لدى الأطفال </strong></p><p dir="RTL"><em>للأطفال ذوي وظائف الكلى الطبيعية: </em></p><p dir="RTL">الجرعة الموصى بها للأطفال:</p><ul dir="rtl"><li>الالتهاب الرئوي، التهابات المسالك البولية، عدوى الجلد والأنسجة تحت الجلد:<ul><li>الأطفال الذين تزيد أعمارهم عن شهرين وتبلغ أوزانهم 40 كغم أو أقل: 50 ملغم/كغم كل 12 ساعة لمدة 10 أيام؛ في حالات العدوى الأشد، يجب الفصل بين الجرعات بفترة 8 ساعات.</li></ul></li><li>الإصابة بتجرثم الدم المرتبط، أو الذي يشتبه ارتباطه بحالات العدوى، التهاب السحايا البكتيري، والعلاج التجريبي لقلة العدلات الحموية:<ul><li>الأطفال الذين تزيد أعمارهم عن شهرين وتبلغ أوزانهم 40 كغم أو أقل: 50 ملغم/كغم كل 8 ساعات خلال فترة تتراوح بين 7 و10 أيام.</li></ul></li></ul><p dir="RTL">تجربة الدواء مع الأطفال الذين تقل أعمارهم عن شهرين محدودة. يجب مراقبة الأطفال في هذا العمر بعناية أثناء إعطاء سيفيبيم.</p><p dir="RTL">يُوصى بإعطاء جرعة البالغين للأطفال الذين تزيد أوزانهم عن 40 كغم.</p><p dir="RTL">لا تتجاوز الجرعة القصوى الموصى بها للبالغين (2000 ملغم كل 8 ساعات). تجربة إعطاء الدواء عن طريق العضل في الأطفال محدودة.</p><p dir="RTL"><em>كبار السن ومرضى القصور الكُلوي ومرضى غسيل الكلى والأطفال الذين يعانون من خلل في وظائف الكلى:</em></p><p dir="RTL">سوف يحدد الطبيب الجرعة التي سيتم إعطائها.</p><p dir="RTL"><strong>إذا استخدمت </strong><strong>سيفافور</strong> <strong>أكثر من اللازم</strong></p><p dir="RTL">اتصل بطبيبك أو غيره من اختصاصيي الرعاية الصحية على الفور، حيث قد تُصاب بآثار جانبية أخطر في حالات معينة.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب، الصيدلي، أو الممرض</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">قد يُحدث سيفيبيم واحداً أو أكثر من الآثار الجانبية التالية:</p><p dir="RTL"><strong>آثار جانبية شائعة جداً</strong> (يُمكن أن تؤثر في أكثر من شخص واحد من بين كل 10 أشخاص):</p><ul dir="rtl"><li>اختبار كومبس الإيجابي دون انحلال الدم (طريقة تحديد مستويات الأجسام المضادة)</li></ul><p dir="RTL"><strong>آثار جانبية شائعة </strong>(قد تؤثر فيما يصل إلى شخص واحد من بين كل 10 أشخاص):</p><ul dir="rtl"><li>زيادة وقت تخثر الدم (زيادة زمن البروثرومبين أو الثرومبوبلاستين)</li><li>فقر الدم</li><li>ارتفاع مستوى بعض خلايا الدم (كثرة اليوزينيات)</li><li>التهاب وريدي في موضع التسريب</li><li>إسهال</li><li>طفح جلدي</li><li>رد تفاعل في موضع التسريب</li><li>ألم والتهاب في موضع الحقن</li><li>ارتفاع مستوى تعداد دم معين (ألانين أمينوترانسفيراز، أسبارتات أمينوترانسفيراز، بيليروبين، الفوسفاتيز القلوي).</li></ul><p dir="RTL"><strong>آثار جانبية غير شائعة</strong> (قد تؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص):</p><ul dir="rtl"><li>التهابات فطرية بالفم مصحوبة بطلاء أبيض (مرض المبيضات الفموي)</li><li>عدوى مهبلية</li><li>انخفاض مستويات بعض خلايا الدم (قلة الصفيحات، قلة الكريات البيض، قلة العدلات)</li><li>نوبات صداع</li><li>التهاب القولون (التهاب الأمعاء الغليظة)</li><li>التهاب القولون الغشائي الكاذب</li><li>غثيان</li><li>قيء</li><li>حمامي (احمرار الجلد)</li><li>الشرى</li><li>حكة</li><li>ارتفاع يوريا الدم</li><li>ارتفاع كرياتينين مصل الدم</li><li>حمّى</li><li>التهاب في موضع الحقن</li></ul><p dir="RTL"><strong>آثار جانبية نادرة </strong>(قد تؤثر فيما يصل إلى شخص واحد من بين كل 1000 شخص):</p><ul dir="rtl"><li>التهابات فطرية (داء المبيضات)</li><li>ردود الفعل التحسسية</li><li>وذمة وعائية (تورم مفاجئ في الجلد، النسيج تحت الجلد، الغشاء المخاطي أو تحت المخاطية)</li><li>التشنجات</li><li>تنميل</li><li>تغيرات في حاسة التذوق</li><li>دوخة</li><li>تمدد الأوعية الدموية</li><li>ضيق التنفس</li><li>ألم في البطن</li><li>إمساك</li><li>حكة في الأعضاء التناسلية</li><li>قشعريرة</li></ul><p dir="RTL"><strong>آثار جانبية غير معروفة</strong> (تكرار غير معروف):</p><ul dir="rtl"><li>فقر الدم اللاتنسجي، فقر الدم الانحلالي وندرة المحببات</li><li>ارتباك</li><li>هلوسة</li><li>غيبوبة</li><li>خدر</li><li>اعتلال دماغي (مرض دماغي غير التهابي)</li><li>اضطراب الوعي</li><li>رمع عضلي (تقلص عضلي)</li><li>النزيف</li><li>مرض معدي معوي</li><li>تفاعلات جلدية شديدة (مثل انحلال البشرة التسممي، متلازمة ستيفنز جونسون وحمامي عديدة الأشكال)</li><li>فشل كلوي</li><li>اعتلال الكلية السمي (تلف الكلى)</li><li>نتائج اختبار جلوكوز البول الإيجابية الكاذب</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL"><strong>بعد الحلّ/التخفيف</strong></p><p dir="RTL">تم إثبات الاستقرار الفيزيائي والكيميائي خلال فترة الاستخدام وذلك لمدة 24 ساعة عند درجة حرارة الغرفة ولمدة 7 أيام داخل الثلاجة (2-8&deg; مئوية).</p><p dir="RTL">من وجهة النظر الميكروبيولوجية، يجب استخدام المستحضر على الفور. في حال عدم استخدامه على الفور، تقع مسؤولية فترات التخزين أثناء الاستخدام وظروف التخزين قبل الاستخدام على المستخدم وعادةً يجب ألا تزيد عن 24 ساعة عند 2-8&deg; مئوية، إلا إذا تم الحل في ظروف تم التحقق أنها معقمة ومسيطر عليها.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد السيفيبيم أحادي الماء.</p><p dir="RTL">تحتوي كل زجاجة من سيفافور 1000 ملغم مسحوق للحل للحقن/للتسريب على هيدروكلوريد السيفيبيم أحادي الماء يكافئ 1000 ملغم سيفيبيم.</p><p dir="RTL">تحتوي كل زجاجة من سيفافور 2000 ملغم مسحوق للحل للحقن/للتسريب على هيدروكلوريد السيفيبيم أحادي الماء يكافئ 2000 ملغم سيفيبيم.</p><p dir="RTL">المادة الأخرى المستخدمة في التركيبة التصنيعية هي ل-أرجينين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيفافور 1000 ملغم مسحوق للحل للحقن/للتسريب هو مسحوق أبيض مائل للأبيض المصفر، متجانس وخالٍ من الجسيمات المرئية في زجاجات بحجم 10 مللتر من النوع رقم ثلاثة مع سدادات مطاطية رمادية اللون وأغطية قابلة للفتح لأعلى.</p><p dir="RTL">سيفافور 2000 ملغم مسحوق للحل للحقن/للتسريب هو مسحوق أبيض مائل للأبيض المصفر، متجانس وخالٍ من الجسيمات المرئية في زجاجات بحجم 50 مللتر من النوع رقم اثنين مع سدادات مطاطية رمادية اللون وأغطية قابلة للفتح لأعلى.</p><p dir="RTL">بعد الحلّ، يكون لون المحلول ما بين الأصفر والأصفر البني.</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم &deg;8, 8A e 8B، فارفانسا<br />906-2705 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +<br /><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 05/2023؛ رقم النسخة SA2.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cefafour 2000 mg Powder for Solution for Injection/Infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains cefepime hydrochloride monohydrate equivalent to 2000 mg cefepime. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection/infusion. 

White to off-white powder, uniform and free from visible particles. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefafour is indicated in the treatment of infections caused by bacteria that are cefepime-sensitive:</p><ul><li>Lower respiratory tract infections, including nosocomial pneumonia and community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and secondary bacterial infection of acute bronchitis;</li><li>Uncomplicated and complicated urinary tract infections, including pyelonephritis;</li><li>Skin and subcutaneous infections;</li><li>Intra-abdominal infections, including peritonitis and biliary tract infections;</li><li>Gynaecological infections;</li><li>Bacterial meningitis in infants and children;</li><li>In combination with other antibacterial agents in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection;</li><li>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</li></ul><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefafour can be administered via intravenous use or intramuscular use.</p><p>After reconstitution, the solution is yellow to yellow-brown.</p><p>The usual dose and the route of administration vary in accordance with the severity of the infection, the renal function and the general conditions of the patient.</p><p>The IV route of administration is preferable in the patients with severe infections or in a life-threatening situation, particularly if there is the possibility of shock.</p><p>Adults and children weighing &gt; 40 kg with normal renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Severity of the infection</strong></p></td><td style="vertical-align:top"><p><strong>Dosage and route of administration</strong></p></td><td style="vertical-align:top"><p><strong>Interval between the doses</strong></p></td></tr><tr><td><p>Mild to moderate urinary tract infections (UTI)</p></td><td><p>500 mg to 1000 mg IV or IM</p></td><td><p>every 12 h</p></td></tr><tr><td><p>Other mild to moderate infections (non UTI)</p></td><td><p>1000 mg IV or IM</p></td><td><p>every 12 h</p></td></tr><tr><td><p>Severe infections</p></td><td><p>2000 mg IV</p></td><td><p>every 12 h</p></td></tr><tr><td><p>Very severe or life-threatening infections</p></td><td><p>2000 mg IV</p></td><td><p>every 8 h</p></td></tr></tbody></table><p>The usual treatment duration is 7 to 10 days; more severe infections can require a more prolonged treatment. In the empirical treatment of febrile neutropenia, the usual treatment duration should not be less than 7 days or until the resolution of the neutropenia.</p><p>In patients weighing &le; 40 kg, the posology indicated for the children is recommended.</p><p><strong>Elderly:</strong></p><p>No dose adjustment is required in patients with normal renal function; the dose adjustment is recommended in patients with impaired renal function (see section 4.4).</p><p><strong>Adults with renal insufficiency:</strong></p><p>The cefepime dose should be adjusted to compensate the slower renal elimination rate. In adult patients with mild to moderate renal insufficiency, the initial dose of cefepime recommended should be the same as for patients with normal renal function. The recommended maintenance dose should be in accordance with the instructions of the table below.</p><p>When only the serum creatinine values are available, the (Cockcroft and Gault) formula can be used to calculate the creatinine clearance. The serum creatinine should represent a steady-state of renal function:</p><p>Man: Creatinine clearance (ml/min) = weight (kg) x (140 - age)</p><p>72 x serum creatinine (mg/dl)</p><p>Woman: 0.85 x value calculated using the man formula</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p><p><strong>(ml/min)</strong></p></td><td colspan="4"><p><strong>Recommended maintenance dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&gt; 50</p></td><td colspan="4" style="vertical-align:top"><p>Usual dose, no dose adjustment is required</p></td></tr><tr><td style="vertical-align:top"><p>2000 mg, 3x day</p><p>2x day</p></td><td style="vertical-align:top"><p>2000 mg, 2x day</p></td><td style="vertical-align:top"><p>1000 mg, 2x day</p></td><td style="vertical-align:top"><p>500 mg,</p></td></tr><tr><td style="vertical-align:top"><p>30 to 50</p></td><td style="vertical-align:top"><p>2000 mg, 2x day</p></td><td style="vertical-align:top"><p>2000 mg, 1x day</p></td><td style="vertical-align:top"><p>1000 mg, 1x day</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td></tr><tr><td style="vertical-align:top"><p>11 to 29</p></td><td style="vertical-align:top"><p>2000 mg, 1x day</p></td><td style="vertical-align:top"><p>1000 mg, 1x day</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10</p></td><td style="vertical-align:top"><p>1000 mg, 1x day</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td><td style="vertical-align:top"><p>250 mg, 1x</p><p>day</p></td><td style="vertical-align:top"><p>250 mg, 1x</p><p>day</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis*</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td><td style="vertical-align:top"><p>500 mg, 1x</p><p>day</p></td></tr></tbody></table><p>*The pharmacokinetic models indicate that it is necessary to reduce the dose in these patients. In patients receiving cefepime and doing haemodialysis, the dose is 1000 mg as loading dose in the first day of treatment followed by 500 mg daily for all the infections, except febrile neutropenia which is 1000 mg daily. In the dialysis days, cefepime should be administered after dialysis. Cefepime should be administered, whenever possible, at the same time every day.</p><p><strong>Patients doing dialysis</strong></p><p>In the patient doing dialysis, about 68% of the total quantity of cefepime present in the body in the beginning of the dialysis will be removed during a 3 hour dialysis. In the patient doing continuous ambulatory peritoneal dialysis, cefepime can be administered in the same dosages that are recommended for the patients with normal renal function, i.e. 500 mg, 1000 mg or 2000 mg, depending on the severity of the infection, but with an interval of 48 hours between doses.</p><p><strong>Children with normal renal function</strong></p><p>In the child, the usual recommended dose is:</p><p><em>Pneumonia, urinary tract infection, skin and subcutaneous tissue infection:</em></p><ul><li>Children aged more than 2 months and weighing &le; 40 kg: 50 mg/kg every 12 hours for 10 days; in more severe infections, 8 hours interval between the intakes should be done.</li></ul><p><em>Bacteraemia that occurs in association with infections, bacterial meningitis and empirical treatment of febrile neutropenia:</em></p><ul><li>Children aged more than 2 months and weighing &le; 40 kg: 50 mg/kg every 8 hours for 7 to 10 days.</li></ul><p>The experience in children aged less than 2 months is limited. Despite the experience having been obtained with the 50 mg/kg dose, data from pharmacokinetic models obtained in children aged more than 2 months suggest that, in children from 1 month to 2 months old, a dose of 30 mg/kg every 12 or 8 hours can be considered. The administration of Cefafour in these patients should be carefully monitored.</p><p>In the child weighing &gt; 40 kg, it is recommended to use the dose indicated for adults. The maximum recommended dose for adults (2000 mg every 8 hours) should not be exceeded. The experience with the intramuscular use in children is limited.</p><p><strong>Children with renal insufficiency:</strong></p><p>As renal excretion is the main route of elimination of cefepime, the dose should be adjusted in children with renal insufficiency. A dose of 50 mg/kg in children from 2 months to 12 year old and a dose 30 mg/kg in children 1 month to 2 months are comparable to a 2000 mg dose in the adult.</p><p>The same interval between the doses is recommended or the same dose reduction indicated for the renal insufficient adult.</p><p><strong>Patients with hepatic function impairment:</strong></p><p>No dose adjustment is required in patients with hepatic insufficiency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cefepime, to any other cephalosporin or to any of the excipients listed in section 6.1.

History of severe hypersensitivity reaction (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypersensitivity reactions</strong></p><p>As with all beta-lactam antibacterial agents, severe and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefepime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefepime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefepime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p>Cefepime should be administered with caution to patients with a history of asthma or allergic diathesis. The patient must be carefully monitored during the first administration. If an allergic reaction occurs, treatment must be discontinued immediately.</p><p>Serious hypersensitivity reactions may require epinephrine and other supportive therapy.</p><p>Antibiotics should be administered with caution to patients that have shown some form of allergy, particularly to drugs. If there is an allergic reaction to Cefafour, the medicine should be stopped and adequate treatment applied.</p><p><em>Antibacterial activity of cefepime</em></p><p>Due to the relatively limited spectrum of antibacterial activity of cefepime it is not suitable for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a very high suspicion that the most likely pathogen(s) would be suitable for treatment with cefepime (see section 5.1).</p><p>As with other antibiotics, the use of Cefafour can lead to the development of resistant micro-organisms. If superinfection occurs during treatment, adequate measures should be taken.</p><p><em>Renal impairment</em></p><p>In patients with impaired renal function, such as reduction of urinary output because of renal insufficiency (creatinine clearance &le; 50 ml/min) or other conditions that may compromise renal function, the dosage of cefepime should be adjusted to compensate for the slower rate of renal elimination. Because high and prolonged serum antibiotic concentrations can occur from usual dosages in patients with renal insufficiency or other conditions that may compromise renal function, the maintenance dosage should be reduced when cefepime is administered to such patients. Continued dosage should be determined by degree of renal impairment, severity of infection and susceptibility of the causative organisms (see sections 4.2 and 5.2).</p><p>During post-marketing surveillance, the following serious adverse events have been reported: reversible encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, seizures (including non-convulsive status epilepticus), and/or renal failure (see section 4.8 - Undesirable effects). Most cases occurred in patients with renal impairment who received doses of cefepime that exceeded the recommendations.</p><p>In general, symptoms of neurotoxicity resolved after discontinuation of cefepime and/or after haemodialysis, however, some cases included a fatal outcome.</p><p><em>Clostridium difficile associated diarrhoea</em></p><p>Antibiotic-associated diarrhoea and antibiotic-associated colitis, including pseudomembranous colitis and Clostridium difficile-associated diarrhoea, has been reported in association with the use of nearly all antibiotics including cefepime and may range in severity from mild diarrhoea to fatal colitis. Therefore, it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of cefepime. If antibiotic-associated diarrhoea or antibiotic-associated colitis is suspected or confirmed, ongoing treatment with antibacterial agents, including cefepime, should be discontinued and adequate therapeutic measures should be initiated immediately. Drugs inhibiting peristalsis are contraindicated in this situation.</p><p>It is known that cefepime is excreted substantially by the kidney and the risk of toxic reactions to this drug can be higher in the patients with renal insufficiency. Because elderly patients are more susceptible to have a decreased renal function, caution should be taken in the selection of the dose and renal function should be monitored (see section 5.2). In elderly patients with renal failure to whom the usual dose of cefepime was administered, severe adverse events occurred (see section 4.8) including reversible encephalopathy (conscience disturbance, including confusion, hallucinations, stupor and coma), myoclonus, convulsions (including non-convulsive status epilepticus) and/or renal failure.</p><p><em>Interference with serological testing</em></p><p>A positive Coombs test, without evidence of haemolysis, has been described in patients treated with cefepime twice daily.</p><p>Cephalosporin antibiotics may produce a false-positive reaction for glucose in the urine with copper reduction tests (Benedict&#39;s or Fehling&#39;s solution or with Clinitest tablets), but not with enzyme-based tests (glucose oxidase) for glycosuria. Therefore, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant treatment with bacteriostatic antibiotics may interfere with the action of beta-lactam antibiotics.</p><p>The monitoring of renal function is recommended during the treatment with Cefafour if other drugs that have nephrotoxic potential are administered (i.e., aminoglycosides and potent diuretics).</p><p>Cephalosporins can potentiate the action of coumarin anticoagulants.</p><p><em>Interaction with diagnostic tests</em></p><p>In patients treated with Cefafour positive Coombs test was described with no evidence of haemolysis.</p><p>In the glycosuria test, a false positive result may occur due to reduction of copper (the enzymatic method should preferably be used).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>In what concerns cefepime there are no sufficient data on its exposure in pregnancy.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, labour or post-natal development (see section 5.3).</p><p>This medicinal product should only be prescribed to pregnant women with great caution.</p><p><strong>Breastfeeding</strong></p><p>Cefepime is excreted in human milk in very low quantities, so caution is recommended when administered to the breast-feeding woman.</p><p><strong>Fertility</strong></p><p>There are no data on the use of cefepime in human fertility. Reproduction studies in animals did not reveal any effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of the medicinal product on the ability to drive and use machines have not been studied.&nbsp;However, possible adverse reactions like altered state of consciousness,&nbsp;dizziness, confusional state or hallucinations may alter the ability to drive and use machines (see sections 4.4, 4.8 e 4.9).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials (N=5598), the more common adverse events were gastrointestinal symptoms and hypersensitivity reactions. The undesirable effects considered as definitively, probably or possibly related to cefepime are listed.</p><p>The frequency of adverse reactions listed below, reported during the clinical experience or post-marketing experience, is defined using the following convention:</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt; 1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt; 1/10,000) and</p><p>Not known (cannot be estimated from the available data).</p><p>The side effects are presented by decreasing order of severity within each class of frequency.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA term</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oral candidiasis, vaginal infection</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Candidiasis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia, eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia, leukopenia, neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Aplastic anaemia<sup>a</sup>, haemolytic anaemia<sup>a</sup>, agranulocytosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Anaphylactic shock</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>State of confusion, hallucination</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Nervous system Disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Headaches</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Convulsions, paraesthesia, digeusia, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Coma, stupor, encephalopathy, altered state of conscience, myoclonus</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Phlebitis at the infusion site</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vasodilatation</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pseudomembranous colitis, colitis, nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Gastrointestinal disorder</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Skin rash</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Erythema, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis<sup>a</sup>, Stevens-Johnson syndrome, erythema multiforme</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood urea increased, blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure, toxic nephropathy<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Genital pruritus</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infusion site reaction, injection site inflammation and pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pyrexia, infusion site inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Chills</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Positive Coombs test</p></td></tr><tr><td rowspan="2" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Alkaline phosphatase increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, prothrombin time prolonged, partial thromboplastin time prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>False positive glycosuria</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&ndash; Adverse reactions generally accepted as being attributable to other compounds of the same class.</p><p>The safety profile of cefepime in infants and children is similar to that seen in the adult.</p><p>As with other drugs of the class of cephalosporins, encephalopathy (conscience disorder, including confusion, hallucinations, stupor and coma), convulsions, myoclonus and/or renal failure were reported. Most cases occurred in patients with renal impairment which received cefepime doses that exceeded those recommended (see section 4.4).</p><p>Such as with other cephalosporins, anaphylaxis, including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis and thrombocytopenia were reported.</p><p>During clinical tests, changes in laboratory tests were transient in the patients with normal baseline values. The changes that occurred with a frequency between 1% and 2% (except when indicated other frequency) were: increased alanine aminotransferase (3.6%), aspartate aminotransferase (2.5%), alkaline phosphatase, total bilirubin, anaemia, eosinophilia, increased prothrombin time and thromboplastin time (2.8%) and positive Coombs test with no haemolysis (18.7%). The transient increases of uraemia, serum creatinine and thrombocytopenia were observed in 0.5% to 1% of the patients. Transient leukopenia and neutropenia were observed (&lt; 0.5%).</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of severe overdose, especially in patients with renal function impairment, haemodialysis can help remove cefepime from the body (peritoneal dialysis is not useful).</p><p>Accidental overdose occurred with the administration of high doses to patients with decreased renal function (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use. Other beta-lactam antibacterials. Fourth-generation cephalosporins, ATC code: J01DE01</p><p><strong>Mechanism of action</strong></p><p>Cefepime is a broad-spectrum, bactericidal antibiotic, with activity against a wide range of Gram-positive and Gram-negative bacteria, including many strains resistant to aminoglycosides or third generation cephalosporins.</p><p>It is highly resistant to hydrolysis caused by most beta-lactamases. It has a reduced affinity for beta-lactamases changed via chromosomes and has a rapid penetration in the cells of the Gram-negative bacteria.</p><p><strong>Resistance</strong></p><p>The bacterial resistance to cefepime can depend on one or several mechanisms:</p><ul><li>Hydrolysis via beta-lactamases. Cefepime is stable to most beta-lactamases changed by plasmids and via chromosomes, but it can be hydrolysed effectively by certain beta-lactamases with broad-spectrum which are present mostly in&nbsp;<em>Escherichia coli</em>&nbsp;and&nbsp;<em>Klebsiella pneumoniae</em>&nbsp;and by enzymes changed by the chromosomes.</li><li>Reduced affinity of the penicillin-binding proteins (PBPS) to cefepime. The resistance developed to&nbsp;<em>Streptococcus pneumoniae</em>&nbsp;and other streptococci caused by PBPs mutation; resistance of the staphylococci to methicillin caused by the production of additional PBPs with reduced affinity to cefepime.</li><li>Non penetrable exterior membrane.</li><li>Drugs efflux pumps.</li></ul><p>There may be simultaneously more than one mechanism of resistance in each cell wall.</p><p>Depending on the mechanism(s) present, there may be crossed resistance to several or to all other beta-lactam and/or antibacterial drugs of other types.</p><p>During treatment, resistance to the following species can develop:&nbsp;<em>Citrobacter</em>,&nbsp;<em>Pseudomonas&nbsp;</em>(especially<em>&nbsp;P. aeruginosa</em>),<em>&nbsp;Morganella&nbsp;</em>and<em>&nbsp;Serratia</em>.</p><p><strong>Critical concentration values (Breakpoints)</strong></p><p>The critical concentration values to differentiate susceptible (S) pathogens from resistant (R) pathogens, in accordance with EUCAST (2009-05-25) are:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p>Critical concentration values related to species</p></td><td style="vertical-align:top"><p>non S &le; 4 mg/l</p></td><td style="vertical-align:top"><p>R &gt; 8 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>S &le; 1 mg/l</p></td><td style="vertical-align:top"><p>R &gt; 8 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas<sup>a</sup></em></p></td><td style="vertical-align:top"><p>S &le; 8 mg/l</p></td><td style="vertical-align:top"><p>R &gt; 8 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>S &le; 0.25 mg/l</p></td><td style="vertical-align:top"><p>R &gt; 0.25 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>and&nbsp;<em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>S &le; 1 mg/l</p></td><td style="vertical-align:top"><p>R &gt; 2 mg/l</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococci&nbsp;</em>A, B, C and G<sup>b</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus<sup>c</sup></em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>a</sup>&nbsp;Critical concentration value is valid in high dose (2g x 3).</p><p><sup>b</sup>&nbsp;Based on the critical concentration value for benzylpenicillin.</p><p><sup>c</sup>&nbsp;Based on the critical concentration value for methicillin.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and it is desirable to have local information on resistance, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in, at least some types of infections, is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gram-positive aerobes</p></td><td style="vertical-align:top"><p><em>Staphylococcus aureus&nbsp;</em>and coagulase negative staphylococci including beta-lactamase producing strains</p><p>Streptococci. Pneumococci</p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative aerobes</p></td><td style="vertical-align:top"><p><em>Acinetobacteria</em></p><p><em>Aeromonas spp</em></p><p><em>Citrobacter</em></p><p>Enterobacteriae</p><p><em>Escherichia coli</em></p><p><em>Haemophilus influenzae&nbsp;</em>including beta-lactamase producing stains</p><p><em>Klebsiella</em></p><p><em>Moraxella catarrhalis&nbsp;</em>including beta-lactamase producing stains</p><p><em>Morganella morganii</em></p><p><em>Proteus</em></p><p><em>Providencia</em></p><p><em>Pseudomonas</em></p><p><em>Serratia</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species with acquired resistance</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gram-positive aerobes</p></td><td style="vertical-align:top"><p><em>Enterococos</em></p><p><em>Listeria</em></p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative aerobes</p></td><td style="vertical-align:top"><p><em>Burkholderia cepacia</em></p><p><em>Legionella</em></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p>Anaerobes</p></td><td style="vertical-align:top"><p>Anaerobic bacteria including&nbsp;<em>Bacteroides and Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top"><p>Other microorganisms</p></td><td style="vertical-align:top"><p><em>Chlamydia</em></p><p><em>Mycoplasma</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Cefepime is completely absorbed after IM administration.</p><p><strong>Distribution</strong></p><p>Adults: Average plasma concentrations of cefepime observed in the male adult, after a single IV infusion (30 minutes) or after the IM injection of doses of 500 mg, 1000 mg and 2000 mg are summarized in table 1; in table 2 are presented the average concentrations in the tissues and biological fluids. After the intramuscular administration, cefepime is completely absorbed.</p><p>Table 1: Average plasma concentrations of cefepime (micrograms/ml)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Cefepime dose</strong></p></td><td style="vertical-align:top"><p><strong>0.5 h</strong></p></td><td style="vertical-align:top"><p><strong>1 h</strong></p></td><td style="vertical-align:top"><p><strong>2 h</strong></p></td><td style="vertical-align:top"><p><strong>4 h</strong></p></td><td style="vertical-align:top"><p><strong>8 h</strong></p></td><td style="vertical-align:top"><p><strong>12 h</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>500 mg IV</strong></p></td><td style="vertical-align:top"><p>38.2</p></td><td style="vertical-align:top"><p>21.6</p></td><td style="vertical-align:top"><p>11.6</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>1000 mg IV</strong></p></td><td style="vertical-align:top"><p>78.7</p></td><td style="vertical-align:top"><p>44.5</p></td><td style="vertical-align:top"><p>24.3</p></td><td style="vertical-align:top"><p>10.5</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>2000 mg IV</strong></p></td><td style="vertical-align:top"><p>163.1</p></td><td style="vertical-align:top"><p>85.8</p></td><td style="vertical-align:top"><p>44.8</p></td><td style="vertical-align:top"><p>19.2</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>500 mg IM</strong></p></td><td style="vertical-align:top"><p>8.2</p></td><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>12.0</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>1000 mg IM</strong></p></td><td style="vertical-align:top"><p>14.8</p></td><td style="vertical-align:top"><p>25.9</p></td><td style="vertical-align:top"><p>26.3</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>2000 mg IM</strong></p></td><td style="vertical-align:top"><p>36.1</p></td><td style="vertical-align:top"><p>49.9</p></td><td style="vertical-align:top"><p>51.3</p></td><td style="vertical-align:top"><p>31.5</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>2.3</p></td></tr></tbody></table><p>Cefepime concentrations in specific tissues and biological fluids are in Table 2.</p><p>The binding of cefepime to serum proteins is, on average, 16.4% and is independent of the serum concentration.</p><p>Table 2: Average concentrations of cefepime in several tissues (micrograms/g) and biological fluids (micrograms/g)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Tissue or Fluid</strong></p></td><td style="vertical-align:top"><p><strong>Dose (IV)</strong></p></td><td style="vertical-align:top"><p><strong>Time after the collection (h)</strong></p></td><td style="vertical-align:top"><p><strong>Average Concentration</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Urine</p></td><td style="vertical-align:top"><p>500 mg</p></td><td style="vertical-align:top"><p>0 &ndash; 4</p></td><td style="vertical-align:top"><p>292</p></td></tr><tr><td style="vertical-align:top"><p>1000 mg</p></td><td style="vertical-align:top"><p>0 &ndash; 4</p></td><td style="vertical-align:top"><p>926</p></td></tr><tr><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>0 &ndash; 4</p></td><td style="vertical-align:top"><p>3120</p></td></tr><tr><td style="vertical-align:top"><p>Bile</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>17.8</p></td></tr><tr><td style="vertical-align:top"><p>Peritoneal fluid</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>18.3</p></td></tr><tr><td style="vertical-align:top"><p>Blister fluid</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>81.4</p></td></tr><tr><td style="vertical-align:top"><p>Bronchial mucosa</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>24.1</p></td></tr><tr><td style="vertical-align:top"><p>Expectoration</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>7.4</p></td></tr><tr><td style="vertical-align:top"><p>Prostate</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>31.5</p></td></tr><tr><td style="vertical-align:top"><p>Appendix</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>5.2</p></td></tr><tr><td style="vertical-align:top"><p>Gall bladder</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>11.9</p></td></tr></tbody></table><p><strong>Biotransformation</strong></p><p>Cefepime is metabolised in N-methylpyrrolidinium, being converted quickly in N-oxide. About 85% of the administered dose is eliminated unchanged; high concentrations of unchanged cefepime are detected in urine. Less than 1% of the administered dose is eliminated in urine as N-methylpyrrolidinium, 6.8% as N-oxide and 2.5% as cefepime epimer.</p><p><strong>Elimination</strong></p><p>The elimination average half-life of cefepime is about 2 hours, and is independent of the dose for the range of 250 mg to 2000 mg. There is no evidence of accumulation in the healthy individuals receiving doses up to 2000 mg IV every 8 hours for 9 days. The total body clearance is 120 ml/min. The average renal clearance of cefepime is 110 ml/min, suggesting an elimination almost exclusively via the kidneys, mainly by glomerular filtration.</p><p><strong>Pharmacokinetic/pharmacodynamic (PK/PD) relationship</strong></p><p>The antibacterial activity depends on the time during which the free concentration serum/urine exceeds the minimum inhibitory concentration (MIC).</p><p><strong>Special populations</strong></p><p><em>Renal dysfunction:&nbsp;</em>The elimination half-life is increased in patients with several degrees of renal failure, so the dosage adjustment is recommended.</p><p><em>Liver dysfunction:&nbsp;</em>Cefepime pharmacokinetics was not changed in patients with hepatic insufficiency that received a dose of 1000 mg. It is not necessary to change the posology of Cefafour in this population.</p><p><em>Elderly:&nbsp;</em>healthy voluntary individuals of 65 years old or more that received a single dose of 1000 mg IV of cefepime presented higher AUC values and lower renal clearance values when compared with younger adults.</p><p>It is recommended the dose adjustment in the elderly patient with renal function impairment (see sections 4.2 and 4.4).</p><p>From the more than 6400 adults treated with cefepime in clinical studies, 35% were aged 65 years old or more and 16% were aged 75 years old or more. In clinical studies when the elderly patient received the recommended dose for the adult patient, the clinical efficacy and safety were comparable to the clinical efficacy and safety in the non-elderly adult patient, unless the patient had renal failure. There was a mild increase in the elimination half-life time and lower renal clearance values when compared with those seen in younger individuals. Dose adjustments are recommended if the renal function is impaired (see section 4.2).</p><p><em>Children:&nbsp;</em>Cefepime pharmacokinetics with single and multiple doses was assessed in patients aged between 2.1 months and 11.2 years, with doses 50 mg/kg in IV infusion or IM injection; multiple doses were administered with intervals of 8 or 12 hours for at least 48 hours.</p><p>After the single IV administration, the total clearance was 3.3 ml/min/kg, with a distribution value of 0.3 l/kg. The elimination half-life was 1.7 hour, with an average recovery in urine of unchanged cefepime around 60.4% of the administered dose, being the renal clearance the main route of elimination (2.0 ml/min/kg).</p><p>The average plasma concentrations of cefepime in steady state after the administration of multiple IV doses were similar to those seen after the 1<sup>st</sup>&nbsp;dose, only with mild accumulation after repeated doses.</p><p>After the IM administration in steady state conditions, maximum cefepime plasma concentrations around 68 micrograms/ml were obtained in average in 0.75 hours. The bioavailability was in average 82% after intramuscular administration.</p><p>The cefepime concentrations in cerebrospinal fluid (CSF) in relation to plasma are the following:</p><p>Table 3: Average concentrations in plasma and in CSF in children*</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Sample collection (h)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Plasma concentration (micrograms/ml)</strong></p></td><td style="vertical-align:top"><p><strong>CSF concentration (micrograms/ml)</strong></p></td><td style="vertical-align:top"><p><strong>CSF/plasma relation</strong></p></td></tr><tr><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>67.1 (51.2)</p></td><td style="vertical-align:top"><p>5.7 (7.3)</p></td><td style="vertical-align:top"><p>0.12 (0.14)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>44.1 (7.8)</p></td><td style="vertical-align:top"><p>4.3 (1.5)</p></td><td style="vertical-align:top"><p>0.10 (0.04)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>23.9 (12.9)</p></td><td style="vertical-align:top"><p>3.6 (2.0)</p></td><td style="vertical-align:top"><p>0.17 (0.09)</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>11.7 (15.7)</p></td><td style="vertical-align:top"><p>4.2 (1.1)</p></td><td style="vertical-align:top"><p>0.87 (0.56)</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>4.9 (5.9)</p></td><td style="vertical-align:top"><p>3.3 (2.8)</p></td><td style="vertical-align:top"><p>1.02 (0.64)</p></td></tr></tbody></table><p>* The age of the patients ranged from 3.1 month to 12 years. The patients with suspicion of CNS infection received 50 mg/kg every 8 hours, in 5 to 20 minutes infusion. The plasma and CSF were collected in the times determined in relation to the end of the infusion on the 2<sup>nd</sup>&nbsp;or 3<sup>rd</sup>&nbsp;day of treatment.</p><p><em>Other</em>: clinical improvement was seen with cefepime in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Pharmacokinetics of cefepime did not change in patients with hepatic function impairment which received a single dose of 1000 mg and in patients with cystic fibrosis. No dose adjustment of Cefafour is required in this population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No long term studies were performed in the animal to assess the carcinogenic potential. In <em>in vitro</em> and <em>in vivo</em> genotoxicity tests, cefepime did no show to be genotoxic. In the rat no decreased fertility was seen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; L-arginine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefepime must not be mixed with other medicinal products or solutions except those mentioned in section 6.6 &ldquo;Special precautions for disposal and other handling&rdquo;.</p><p>There is a physical-chemical incompatibility with metronidazole, vancomycin, gentamicin, tobramycin, netilmicin and aminophylline. In the cases where a concomitant intravenous administration is indicated, these active substances should not be administered together with cefepime or through the same intravenous route.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months. 

Reconstituted solution for injection, reconstituted with water for injections:
The in use physical and chemical stability was demonstrated for 24 hours at room temperature and for 7 days in a refrigerator (2-8°C).
From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use time and storage conditions prior to administration are users' responsibility and, usually, should not exceed 24 hours at 2-8°C, unless reconstitution has occurred under validated aseptic controlled conditions.

The reconstituted solution for infusion, reconstituted with other solvents (0.9% sodium chloride solution, 0.9% sodium chloride with 5% dextrose solution, 5% or 10% dextrose solution, Ringer lactate solution, Ringer lactate with 5% dextrose solution, 1/6M Sodium lactate solution):
The in use physical and chemical stability was demonstrated for 24 hours at room temperature and for 7 days in a refrigerator (2-8°C).

Do not refrigerate.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use time and storage conditions prior to administration are users' responsibility, unless reconstitution has occurred under validated aseptic controlled conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50 ml type II vials with grey rubber stoppers and flip-off caps.</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><em>Preparation and administration of the reconstituted solution:</em></p><p>Cefafour powder for solution for injection/infusion should be dissolved in:</p><p>a) water for injections</p><p>or in one of the solutions listed in b) below for intravenous administration</p><p>b) 0.9% sodium chloride solution</p><p>0.9% sodium chloride with 5% dextrose solution</p><p>5% or 10% dextrose solution</p><p>Ringer lactate solution</p><p>Ringer lactate with 5% dextrose solution</p><p>1/6 M sodium lactate solution.</p><p><strong>For Intravenous Injection</strong>, the volume of the solvent to be added to each vial and the resulting concentration of cefepime are presented in the following table:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Quantity of cefepime per vial</strong></p></td><td style="vertical-align:top"><p><strong>Volume of solvent added (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Approximate final volume (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Approximate concentration of cefepime (mg/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1000 mg IV</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>11.4</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>2000 mg IV</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>160</p></td></tr></tbody></table><p><strong>For Intravenous Infusion</strong>, the volume of the solvent for infusion (solution listed in b)) to be used for reconstitution and the resulting concentration of cefepime are presented in the following table:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Quantity of cefepime per vial</strong></p></td><td style="vertical-align:top"><p><strong>Volume of solvent added (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Approximate final volume (ml)</strong></p></td><td style="vertical-align:top"><p><strong>Approximate concentration of cefepime (mg/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1000 mg IV</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>51.4</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>2000 mg IV</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>52.8</p></td><td style="vertical-align:top"><p>38</p></td></tr></tbody></table><p>The resulting solution should be administered over approximately 30 minutes.</p><p><strong>For Intramuscular Injection</strong>, reconstitute the 1000 mg vial by using 3.0 ml of water for injections.</p><p>Note: The&nbsp;reconstituted&nbsp;solutions, which are prepared correctly, can present a yellow to yellow-brown colour. This does not mean that efficacy of Cefafour may be compromised.</p><p>The content of the vial is meant for a single usage. The remaining&nbsp;reconstituted&nbsp;solution should be discarded.</p><p>Inspect the vial before using. It can only be used if the solution does not present particles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 May 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>